EU/3/09/629

About

This medicine is now known as caplacizumab.

On 30 April 2009, orphan designation (EU/3/09/629) was granted by the European Commission to Ablynx NV, Belgium, for nanobody directed towards the human A1 domain of von Willebrand factor for the treatment of thrombotic thrombocytopenic purpura.

Nanobody directed towards the human A1 domain of von Willebrand factor has been authorised in the EU as Cablivi since 31 August 2018.

Key facts

Active substance
Nanobody directed towards the human A1 domain of von Willebrand factor (caplacizumab) 
Medicine name
Cablivi
Disease / condition
Treatment of thrombotic thrombocytopenic purpura
Date of first decision
30/04/2009
Outcome
Positive
EU designation number
EU/3/09/629

Review of designation

The Committee for Orphan Medicinal Products reviewed the orphan designation of Cablivi at the time of marketing authorisation, and confirmed that the orphan designation should be maintained.

More information is available in the PDF iconorphan medicine assessment report .

Sponsor's contact details

Ablynx NV
Technologiepark 21
B-9052 Zwijnaarde
Belgium
Telephone: + 32 92 62 00 00
Telefax: + 32 92 62 00 02
E-mail: info@ablynx.com

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;
  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

How useful was this page?

Add your rating